Flux Power Holdings Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Flux Power Holdings Inc trades at $0.44 (market cap $10.60M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2367× Flux Power Holdings Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| FLUX | ROIV | |
|---|---|---|
Market Cap | $10.60M | $25.09B |
Volume | 892,542 | 5,738,571 |
Sector | Industrials | Health |
52-Week High | $6.66 | $41.81 |
52-Week Low | $0.41 | $16.04 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $18.80M | $21.36B |
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4902, down 0.55% on the day, amid a bearish technical signal with price near recent lows. The company reported a net loss of $6.67 million in 2025, with revenue declining to $42 million in 2026 and a negative net income margin of -17.68%. Recent news highlights a rejected unsolicited acquisition proposal from Solidion Technology, creating uncertainty.
Despite unanimous analyst buy ratings, fundamental challenges persist with negative profitability and cash flow concerns. The stock faces execution risks and competitive pressures, but potential acquisition interest could offer upside. Investors should weigh deteriorating financials against speculative M&A prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →